Gan and Lee Pharmaceuticals (SHSE:603087) Construction In Progress: ¥456 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603087 Gan and Lee Pharmaceuticals SHSE:603087
90 GF Score
Price ¥66.34
GF Value ¥73.00
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gan and Lee Pharmaceuticals Construction In Progress?

Gan and Lee Pharmaceuticals SHSE:603087 -2.27% 90 Construction In Progress is ¥456 Mil as of Jun. 2026. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review.

Gan and Lee Pharmaceuticals's quarterly construction in progress declined from Dec. 2025 (¥393 Mil) to Mar. 2026 (¥358 Mil) but then increased from Mar. 2026 (¥358 Mil) to Jun. 2026 (¥456 Mil).

Gan and Lee Pharmaceuticals's annual construction in progress declined from Dec. 2023 (¥2,007 Mil) to Dec. 2024 (¥1,262 Mil) and declined from Dec. 2024 (¥1,262 Mil) to Dec. 2025 (¥393 Mil).

Gan and Lee Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Gan and Lee Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan and Lee Pharmaceuticals Construction In Progress Chart

Gan and Lee Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 874.91 2,002.73 2,006.96 1,262.03 393.47

Gan and Lee Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,259.97 1,348.30 393.47 357.51 455.97
SHSE:603087
90GF Score
Gan and Lee Pharmaceuticals SHSE:603087
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gan and Lee Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥456 Mil mean?
Gan and Lee Pharmaceuticals (SHSE:603087) has a Construction In Progress of ¥456 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Gan and Lee Pharmaceuticals and its competitors.
Is Gan and Lee Pharmaceuticals' Construction In Progress too high?
Gan and Lee Pharmaceuticals' current Construction In Progress is ¥456 Mil. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Construction In Progress compare to ISRG and BDX?
Gan and Lee Pharmaceuticals' Construction In Progress of ¥456 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Devices & Instruments company?
A good Construction In Progress depends on the Medical Devices & Instruments industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Gan and Lee Pharmaceuticals and its competitors. Gan and Lee Pharmaceuticals's current Construction In Progress is ¥456 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Construction In Progress is ¥456 Mil. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Construction In Progress is ¥456 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?

Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued. The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00. GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.

Key valuation signals for SHSE:603087:

  • Construction In Progress: ¥456 Mil
  • GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gan and Lee Pharmaceuticals Business Description

Address No. 8, Nanfengxi 1st Road, Xianxian Town, Tongzhou District, Beijing, CHN, 101109
Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections.
90GF Score

Get the complete analysis for SHSE:603087

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥66.34
Price
¥73.00
GF Value